CoChat

Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT)

Open access
The Alzheimer's Disease Anti‐inflammatory Prevention Trial Research Group · 2013 · Alzheimer's & Dementia
Cited by 111

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Objectives: The Alzheimer's Disease Anti‐inflammatory Prevention Trial Follow‐up Study (ADAPT‐FS) was designed to evaluate the efficacy of naproxen and celecoxib for the primary prevention of Alzheimer's disease (AD) several years after cessation of treatment in ADAPT. Methods: ADAPT was a randomized, double‐masked, multicenter clinical trial of naproxen or celecoxib vs placebo (1:1:1.5 assignment ratio) at six U.S.‐based clinics. The trial enrolled 2528 people between 2001 and 2004. Treatments were discontinued in December 2004 and participants were monitored regularly until 2007. In 2010 and 2011, ADAPT‐FS screened 1537 participants by telephone and, if indicated, examined them in person using standardized clinical assessments. The primary outcome was time to diagnosis of AD. Death index searches were performed for participants not located. Results: Eighty‐nine additional AD events were identified (24 celecoxib, 25 naproxen, and 40 placebo) yielding a total of 161 events (48 [6.6% of randomized participants] celecoxib, 43 [6.0%] naproxen, and 70 [6.5%] placebo) across ADAPT and ADAPT‐FS. Adjusted hazard ratios (HRs) comparing each treatment with placebo showed no overall reduction in risk of AD: HR celecoxib vs placebo, 1.03 (95% confidence interval [CI], 0.72–1.50; P = .86); HR naproxen vs placebo, 0.92 (95% CI, 0.62–1.35; P = .66). There were 349 deaths (110 [15.2%] celecoxib, 96 [13.4%] naproxen, and 143 [13.2%] placebo). Risk of death was similar for the naproxen‐ and placebo‐assigned groups (HR, 0.99; 95% CI, 0.76–1.28; P = .93) and slightly higher for celecoxib compared with the placebo‐assigned group (HR, 1.15; 95% CI, 0.90–1.48; P = .27). Conclusions: These results acquired during a follow‐up of approximately 7 years (which included a median of less than 1.5 years of treatment) do not support the hypothesis that celecoxib or naproxen prevent AD in adults with a family history of dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.11.012

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 111

Metadata

Authors
The Alzheimer's Disease Anti‐inflammatory Prevention Trial Research Group
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2013-04-05
Volume
9
Issue
6
Pages
714-723
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4236625742
Cited by
111
References
12
FWCI
6.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT). https://app.cochat.ai/papers/10.1016/j.jalz.2012.11.012
The paper
The Alzheimer's Disease Anti‐inflammatory Prevention Trial Research Group. (2013). Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT). Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.11.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.